Meiji Yasuda Asset Management Co Ltd. Buys 16,184 Shares of Boston Scientific Co. (NYSE:BSX)

Meiji Yasuda Asset Management Co Ltd. grew its holdings in Boston Scientific Co. (NYSE:BSX) by 20.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 96,555 shares of the medical equipment provider’s stock after acquiring an additional 16,184 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in Boston Scientific were worth $8,624,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Zions Bancorporation N.A. lifted its stake in Boston Scientific by 9.5% in the fourth quarter. Zions Bancorporation N.A. now owns 3,590 shares of the medical equipment provider’s stock valued at $321,000 after acquiring an additional 310 shares during the last quarter. FineMark National Bank & Trust bought a new position in Boston Scientific during the fourth quarter worth about $206,000. Ashton Thomas Securities LLC boosted its stake in shares of Boston Scientific by 3.5% in the fourth quarter. Ashton Thomas Securities LLC now owns 10,316 shares of the medical equipment provider’s stock valued at $921,000 after buying an additional 348 shares during the period. TD Asset Management Inc. grew its holdings in shares of Boston Scientific by 2.1% during the 4th quarter. TD Asset Management Inc. now owns 2,289,791 shares of the medical equipment provider’s stock worth $204,524,000 after purchasing an additional 46,255 shares in the last quarter. Finally, EFG Asset Management North America Corp. lifted its holdings in shares of Boston Scientific by 9.2% during the 4th quarter. EFG Asset Management North America Corp. now owns 29,930 shares of the medical equipment provider’s stock worth $2,674,000 after acquiring an additional 2,527 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Boston Scientific news, EVP Jeffrey B. Mirviss sold 4,675 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $104.25, for a total transaction of $487,368.75. Following the sale, the executive vice president now owns 28,454 shares in the company, valued at $2,966,329.50. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP John Bradley Sorenson sold 1,201 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the transaction, the executive vice president now owns 25,443 shares of the company’s stock, valued at $2,704,845.33. The trade was a 4.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 137,302 shares of company stock valued at $14,319,269 in the last quarter. Corporate insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Morgan Stanley increased their price objective on shares of Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. Stifel Nicolaus lifted their target price on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Truist Financial increased their price target on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Citigroup upped their price target on Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Finally, Piper Sandler boosted their price objective on Boston Scientific from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Two analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and an average target price of $108.91.

Boston Scientific Trading Up 2.0 %

Shares of BSX opened at $102.74 on Tuesday. Boston Scientific Co. has a twelve month low of $66.80 and a twelve month high of $107.17. The stock has a market cap of $151.96 billion, a PE ratio of 82.19, a P/E/G ratio of 2.79 and a beta of 0.77. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The business’s 50-day moving average price is $101.84 and its 200-day moving average price is $92.65.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, equities analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.